MDS Pharma Services Named Top CRO in Europe
15 Giugno 2006 - 3:00PM
PR Newswire (US)
Recognized by Thomson CenterWatch as a preferred provider of late
phase clinical trial management services KING OF PRUSSIA, PA, June
15 /PRNewswire-FirstCall/ -- MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions,
has been ranked the top contract research organization (CRO) in
Europe in a survey of clinical trial investigators by Thomson
CenterWatch, a leading provider of news, market intelligence and
information services for the clinical research industry. "This
recognition adds to MDS Pharma Services' reputation as a world-
class, market-leading provider of drug discovery and development
solutions, and attests to our commitment to continuously raising
the bar to better serve our clients," said David Spaight,
President, MDS Pharma Services. In the June 2006 issue of
CenterWatch Monthly, MDS Pharma Services earned the top score for
CROs in the publication's survey of 356 European investigative
sites where front-line researchers conduct clinical trials.
Investigators were asked to rate the CROs with which they have
worked over the past two years on a wide range of attributes.
Seventy-nine percent of those surveyed gave MDS Pharma Services
either "Good" or "Excellent" ratings, and the business received
"Excellent" ratings in 14 of 28 attribute areas - more than any
other CRO. MDS Pharma Services was rated "Excellent" in the
critical area of "Organization and Preparation" by 54 percent of
the responding sites, more than any other CRO. "Organization and
Preparation" was the most desired attribute in a CRO, with 83
percent of respondents rating it as "very important". MDS Pharma
Services also out-scored other CROs in every sub- attribute in this
category. Other characteristics in which MDS Pharma Services
excelled include timeliness of drug availability, professionalism
of the medical staff, grant payment fairness, realistic timelines,
and quality of communications with sites. "We consider our
relationships with investigators to be absolutely critical to
getting clients' studies recruited on time and on budget," Spaight
said. "MDS Pharma has distinguished itself as a CRO that excels at
helping clients succeed through exceptional service. The
recognition we've received is a great honor and shows that thanks
to the professionalism and deep commitment of our staff, we are
building a world-class market-leading provider of drug discovery
and development solutions." About MDS Pharma Services MDS Pharma
Services offers a full spectrum of resources to meet the drug
discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically
located around the world, the company applies advanced scientific
and technological expertise to each stage of the drug discovery and
development process - Early Stage: lead optimization, pre-IND
research, pharmaceutical and biopharmaceutical development, early
clinical research (bioequivalence, phases I-IIa) and bioanalysis;
and Late Stage: global clinical development (phases IIb-IV) and
central lab. For more information, visit MDS Pharma Services' Web
site at http://www.mdsps.com/. MDS Pharma Services is an integral
part of MDS Inc. (TSX: MDS; NYSE: MDZ). MDS Inc. has more than
8,800 highly skilled people in 28 countries. It provides a diverse
range of superior products and services to increase customers'
speed, precision and productivity in the drug development and
disease diagnosis processes. MDS is a global, values-driven life
sciences company, recognized for its reliability and collaborative
relationships that help create better outcomes in the treatment of
disease. Find out more at http://www.mdsinc.com/ or by calling
1-800-MDS-7222, 24 hours a day. DATASOURCE: MDS Pharma Services;
MDS Inc. CONTACT: For Investors, Sharon Mathers, (416) 675-6777
ext. 4721, ; For Media, Charlene McGrady, (610) 239-7900 ext. 231.,
Copyright